Tag

Weight Loss Drugs

All articles tagged with #weight loss drugs

health4 hours ago•2 min saved

Mounjaro access in England still a postcode lottery, patient says

Brian Kinsella, who has privately used Mounjaro since December 2024, says he has lost more than 44.5 kg (seven stone) at up to £1,000 a year, highlighting uneven access as England’s NHS rolls out weight‑loss drugs. GPs are to receive £3,000 annually to prescribe these treatments, but since a limited NHS rollout began in June last year not all practices prescribe them. Kinsella expects the new incentives won’t help much due to workload and the system’s complexity, noting the requirement for two 85‑minute consultations, a 20‑minute follow‑up every four weeks, and a 60‑minute dietitian appointment. He calls the situation a “postcode lottery” and says a mechanism is needed to widen access to this drug.

via BBC|

#gp-incentives #health #mounjaro

health2 days ago•4 min saved

England GPs offered £3,000 annual bonus to steer weight‑loss drug prescriptions

England’s health strategy will pay GPs £3,000 a year plus about £1,000 for referring patients to weight‑loss programmes to increase NHS prescriptions of the drug Mounjaro; Wegovy remains prescribed only through NHS weight‑loss services. Access to these drugs on the NHS remains tightly restricted (BMI thresholds and health conditions), with rollout described as patchy. Experts say the incentives may help access but won’t widen eligibility, and concerns about workload and realistic patient eligibility persist as the NHS aims to shift toward prevention and reach an expected 220,000 Mounjaro users by 2028.

via BBC|

#gp-incentives #health #mounjaro

health2 days ago•1 min saved

Weight-Loss Meds Reframe How People Move, Not Just How They Eat

A profile of Jamie Selzler shows how weight‑loss medications can shift a person’s relationship with activity: once he dreaded workouts as punishment, the meds helped him view exercise as something to be proud of, illustrating how pharmacotherapy can change attitudes toward physical activity beyond just weight loss.

via The New York Times|

#exercise-motivation #glp-1 #health

health7 days ago•6 min saved

Are Weight-Loss Drugs Too Effective? New Trials Spark Safety Questions

Trial results for Eli Lilly’s retatrutide show about 28.7% weight loss after 68 weeks, higher than current meds, but with 12–18% dropout due to side effects and some participants reporting they were losing too much weight. Health experts caution about malnutrition and disordered eating, advocating dosing that is tailored to the patient and kept at the lowest effective level as obesity becomes a chronic disease; Novo Nordisk’s CagriSema uses flexible dosing to manage safety as full data from the retatrutide trial await publication.

via The New York Times|

#cagrisema #glp-1 #health

explain-it-to-me9 days ago•36 min saved

Weight‑loss drugs that dull the spark: GLP-1 apathy explored

GLP-1 weight‑loss medications are surging in use, with users commonly reporting fatigue and nausea, but clinicians are noting a striking side effect: extreme apathy or a “flat” emotional state that isn’t classic depression. Experts say it may involve dopamine and motivation pathways, making the net impact nuanced and highly dependent on individual circumstances as more people start these therapies.

via vox.com|

#apathy #explain-it-to-me #flat-affect

wellness11 days ago•10 min saved

Weight-Loss Drugs Getting Cheaper, Doctors Explain Who Qualifies

After Aishwarya Mohanraj’s Mounjaro confession, Soha Ali Khan discusses price with doctors: lower doses around Rs 12,000 per month (recently down to about Rs 10,000), higher doses about Rs 20,000–22,000, with overall monthly costs roughly Rs 12,000–20,000; prices are expected to fall as more companies produce them, but not everyone qualifies—BMI thresholds and co-morbid conditions determine eligibility, and medical supervision is essential due to side effects.

via NDTV|

#bmi-eligibility #mounjaro #price

business15 days ago•3 min saved

Novo Nordisk sues rival over unapproved, knock-off weight-loss drugs

Novo Nordisk has filed a US lawsuit to block Hims & Hers from selling weight‑loss pills and injections it says are unapproved and infringe its patents, arguing safety concerns over compounded versions. The move comes as the FDA tightens rules on compounding, and amid broader pressure from expiring patents on Wegovy/Ozempic; Hims & Hers’ stock fell while Novo Nordisk edged higher following the filing.

via BBC|

#business #fda #hims-and-hers

health17 days ago•54 min saved

Mounjaro reverses liver fibrosis in fatty liver disease, doctors report

Two women with advanced fatty liver disease and fibrosis reportedly saw reversal of liver damage after using Mounjaro, a GLP-1 weight-loss drug. The case adds to growing evidence that treating obesity-related liver disease can reverse scar tissue, but NHS approval is still pending and access remains costly, underscoring the need for more research.

via dailymail.co.uk|

#fatty-liver-disease #glp-1 #health

business21 days ago•4 min saved

Novo Nordisk Braces for 2026 as Weight-Loss Drug Rivalry Intensifies

Novo Nordisk warned that 2026 sales could fall as much as 13% due to fierce competition from Eli Lilly’s weight-loss drugs and government pricing pressure, marking the first annual decline since Ozempic’s launch; Lilly projected continued growth. The company also reported strong early uptake for a pill version of Wegovy and is pursuing a higher 7.2 mg dose, even as leadership shakeups and patent expirations keep the turnaround challenging and sent Novo's shares lower.

via The New York Times|

#business #lilly #novo-nordisk

health26 days ago•2 min saved

UK cautions on rare pancreatitis risk from GLP-1 weight-loss injections

The UK MHRA warns that GLP-1 obesity drugs like Wegovy, Mounjaro, and Ozempic carry a very small but real risk of acute pancreatitis. Users should seek immediate medical attention for severe, persistent stomach pain that may radiate to the back, especially with nausea or vomiting. While hundreds of pancreatitis reports exist, none are confirmed as caused by these medicines. About 1.6 million adults in the UK are estimated to have used GLP-1 products recently. Most patients benefit and are safe, but patients should discuss benefits and risks with their prescriber and report any suspected adverse effects.

via BBC|

#glp-1 #health #mhra

health27 days ago•3 min saved

MHRA Flags Rare Pancreatitis Risk From GLP-1 Weight-Loss Injectables

Britain’s MHRA warns that GLP-1 weight‑loss injections (semaglutide, tirzepatide) carry a small risk of pancreatitis. With about 1.6 million users in 2024–25, the Yellow Card scheme has logged 1,143 cases of pancreatitis (acute and chronic) and 17 deaths among GLP-1 users, most in 2025 (807 tirzepatide, 166 semaglutide). Fewer reports exist for liraglutide and dulaglutide. Patients should watch for severe, persistent abdominal pain with nausea and report suspected adverse reactions, while researchers use the Yellow Card Biobank to study genetic risk. Manufacturers reiterate safety and supervised use.

via The Guardian|

#glp-1 #health #mhra

health27 days ago•16 min saved

Rising GLP-1 Use Triggers Pediatric Overdoses, Poison Centers Warn

GLP-1 medications like Ozempic/Wegovy and Zepbound/Mounjaro, increasingly used for weight loss, have coincided with a surge in poison-center calls and overdoses, including children. A 7-year-old in Indiana suffered severe vomiting after taking her mother's injection; statewide calls rose from 153 in 2024 to 320 in 2025, and national data show about 23,000 GLP-1–related poison-center calls from 2019–2025 (nearly a 1,500% increase). Experts urge proper dosing, buying from reputable sources, and securing meds away from kids, noting counterfeit products add another layer of risk.

via Gizmodo|

#children #glp-1 #health

health27 days ago•8 min saved

7-year-old’s GLP-1 overdose highlights rise of accidental dosing with weight-loss meds

A California family’s 7-year-old daughter overdosed on her mother’s GLP-1 medication (tirzepatide/Mounjaro), causing severe vomiting and dehydration but a full recovery; the incident mirrors a nationwide surge in GLP-1 overdose and side-effect calls to poison centers as prescriptions rise, with most cases due to accidental dosing errors. Experts urge careful reading of instructions, pharmacist demonstrations on proper dosing, use of lockboxes for meds, and obtaining medications from reputable sources to keep them away from children.

via Yahoo|

#children #glp-1 #health

health28 days ago•8 min saved

7-year-old’s GLP-1 overdose spotlights rising safety concerns with popular meds

With GLP-1 prescriptions surging for diabetes and weight loss, a 7-year-old's self-injection and hospitalization spotlight a nationwide rise in GLP-1–related poison-center calls, driven mainly by accidental dosing; experts warn of dehydration, renal risk, and even pancreatitis, urging careful dosing, secure storage, and reputable sourcing to prevent misuse and counterfeit drugs.

via wthr.com|

#dosing-errors #glp-1-medications #health

business1 month ago•6 min saved

GLP-1 weight-loss jabs reshape British shopping habits

Weight-loss injections are changing UK spending patterns: about 1.6 million people used GLP-1 weight-loss jabs in 2024, with private users paying over £300 a month. Users report smaller grocery bills due to reduced appetite and a shift toward nutrient-dense, protein-rich foods, while some still face high drug costs. Dining out and takeaway purchases are down, alcohol intake is dropping for some, and fashion and fitness sectors see increased activity as people replace wardrobes and invest in wellness. The overall effect is a pivot toward health-focused spending, with costs influenced by the drugs themselves.

via BBC|

#business #consumer-spending #glp-1